Skip to main content

Advertisement

SpringerLink
Log in

Real-world effectiveness and safety of ustekinumab and vedolizumab in elderly patients with Crohn’s disease

  • Short Report
  • Published:
Indian Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Studies report favorable efficacy and safety profiles of ustekinumab (UST) and vedolizumab (VDZ) in Crohn’s disease (CD), but effectiveness and safety data in elderly patients with CD is lacking. We retrospectively analyzed 78 elderly patients (39 each UST and VDZ) and found that patients on UST and VDZ experienced similar rates of clinical response, remission and mucosal healing despite high proportion of prior biologic exposure. Both UST and VDZ appear to be effective and safe in this at-risk CD population. Further large studies are needed to validate our findings.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hanauer SB, Sandborn WJ, Feagan BG, et al. IM-UNITI: Three-year efficacy, safety, and immunogenicity of Ustekinumab treatment of Crohn’s disease. J Crohns Colitis. 2020;14:23–32.

  2. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–21.

  3. Panaccione R, Danese S, Sandborn WJ, et al. Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy. Aliment Pharmacol Ther. 2020;52:1658–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Dulai PS, Singh S, Jiang X, et al. The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn’s disease: Results from the US VICTORY Consortium. Am J Gastroenterol. 2016;111:1147–55.

  5. Juneja M, Baidoo L, Schwartz MB, et al. Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity. Dig Dis Sci. 2012;57:2408–15.

    Article  PubMed  Google Scholar 

  6. Garg R, Aggarwal M, Butler R, et al. Real-world effectiveness and safety of Ustekinumab in elderly Crohn’s disease patients. Dig Dis Sci. 2022;67:3138–47.

  7. LeBlanc JF, Wiseman D, Lakatos PL, et al. Elderly patients with inflammatory bowel disease: Updated review of the therapeutic landscape. World J Gastroenterol. 2019;25:4158–71.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Charpentier C, Salleron J, Savoye G, et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut. 2014;63:423–32.

    Article  PubMed  Google Scholar 

  9. Sturm A, Maaser C, Mendall M, et al. European Crohn’s and Colitis organisation topical review on IBD in the elderly. J Crohns Colitis. 2017;11:263–73.

  10. Bohm M, Xu R, Zhang Y, et al. Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn’s disease. Aliment Pharmacol Ther. 2020;52:669–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Narula N, Peerani F, Meserve J, et al. Vedolizumab for ulcerative colitis: Treatment outcomes from the VICTORY Consortium. Am J Gastroenterol. 2018;113:1345.

  12. Cohen NA, Plevris N, Kopylov U, et al. Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study. United European Gastroenterol J. 2020;8:1076–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Shashi P, Gopalakrishnan D, Parikh MP, Shen B, Kochhar G. Efficacy and safety of vedolizumab in elderly patients with inflammatory bowel disease: a matched case-control study. Gastroenterol Rep (Oxf). 2020;8:306–11.

  14. Biemans VBC, van der Woude CJ, Dijkstra G, et al. Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti-TNF treatment. Aliment Pharmacol Ther. 2020;52:123–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Townsend T, Razanskaite V, Dodd S, et al. Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn’s disease. Aliment Pharmacol Ther. 2020;52:1341–52.

    Article  CAS  PubMed  Google Scholar 

  16. Adar T, Faleck D, Sasidharan S, et al. Comparative safety and effectiveness of tumor necrosis factor alpha antagonists and vedolizumab in elderly IBD patients: a multicentre study. Aliment Pharmacol Ther. 2019;49:873–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Ananthakrishnan AN, Shi HY, Tang W, et al. Systematic review and meta-analysis: Phenotype and clinical outcomes of older-onset inflammatory bowel disease. J Crohns Colitis. 2016;10:1224–36.

  18. Geisz M, Ha C, Kappelman MD, et al. Medication utilization and the impact of continued corticosteroid use on patient-reported outcomes in older patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22:1435–41.

  19. Feuerstein JD, Ho EY, Shmidt E, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn’s disease. Gastroenterology. 2021;160:2496–508.

  20. Lichtenstein GR, Loftus EV, Isaacs KL, et al. ACG clinical guideline: Management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113:481–517.

  21. Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: Medical treatment. J Crohns Colitis. 2020;14:4–22.

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic, Cleveland, OH, USA

    Rajat Garg, Jean Paul Achkar, Bret Lashner, Jessica Philpott, Benjamin Cohen, Taha Qazi, Florian Rieder, Miguel Regueiro & Benjamin Click

  2. Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA

    Manik Aggarwal & Abdul Mohammed

Authors
  1. Rajat Garg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manik Aggarwal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Abdul Mohammed
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jean Paul Achkar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bret Lashner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jessica Philpott
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Benjamin Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Taha Qazi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Florian Rieder
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Miguel Regueiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Benjamin Click
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rajat Garg.

Ethics declarations

Conflict of interest

RG, MA, AM, JPA, BL, JP, BC, TQ, FR, MR and BC have no conflict of interest.

Ethics statement

The study was performed conforming to the Helsinki Declaration of 1975, as revised in 2000 and 2008 concerning human and animal rights, and the authors followed the policy concerning informed consent as shown on Springer.com.

Disclosures

RG, MA, RB, JPA, BL and TQ have nothing to disclose.

Jessica Philpott- AbbVie speaker bureau.

Benjamin Cohen has served as a speaker, a consultant, or an advisory board member for AbbVie, Alfasigma, Allergan, Celltrion, Ferring, Grifols, Janssen and Sublimity Therapeutics.

Florian Rieder- Consulting or Advisory Board: Agomab, Allergan, AbbVie, Boehringer-Ingelheim, Celgene/BMS, CDISC, Cowen, Genentech, Gilead, Gossamer, Guidepoint, Helmsley, Index Pharma, Jannsen, Koutif, Mestag, Metacrine, Morphic, Origo, Pfizer, Pliant, Prometheus Biosciences, Receptos, RedX, Roche, Samsung, Surrozen, Takeda, Techlab, Theravance, Thetis, UCB. Funding: NIH, Helmsley Charitable Trust, Crohn’s and Colitis Foundation, UCB, Pliant, BMS, Pfizer, Boehringer Ingelheim, Morphic, Kenneth Rainin Foundation.

Miguel Regueiro- Research Support from AbbVie, Janssen, Takeda, Pfizer. Unrestricted Educational Grants from AbbVie, Janssen, UCB, Pfizer, Takeda, Celgene, Genentech, Gilead. Advisory Boards and Consultant for AbbVie, Janssen, UCB, Takeda, Pfizer, Miraca Labs, Amgen, Celgene, Seres, Allergan, Genentech, Gilead, Salix, Prometheus, Lilly, TARGET Pharma Solutions, ALFASIGMA, S.p.A. CME Companies: CME Outfitters, Imedex, GI Health Foundation (GiHF), Cornerstones, Remedy, MJH L Sciences. Royalties: Wolters Kluwer Health as Author/Editor of UpToDate.

Benjamin Click – Consulting and speakers bureau – Takeda; consulting – TARGET-RWE, consulting—MedEd.

Disclaimer

The authors are solely responsible for the data and the content of the paper. In no way, the Honorary Editor-in-Chief, Editorial Board Members, the Indian Society of Gastroenterology or printer/publishers are responsible for the results/ findings and content of this article.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 75 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Garg, R., Aggarwal, M., Mohammed, A. et al. Real-world effectiveness and safety of ustekinumab and vedolizumab in elderly patients with Crohn’s disease. Indian J Gastroenterol 42, 718–723 (2023). https://doi.org/10.1007/s12664-023-01391-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12664-023-01391-3

Keywords

Search

Navigation